Alnylam Pharmaceuticals
ALNY
#570
Rank
ยฃ32.36 B
Marketcap
ยฃ244.07
Share price
-2.03%
Change (1 day)
24.03%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Revenue for Alnylam Pharmaceuticals (ALNY)

Revenue in 2024: ยฃ1.79 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current revenue (TTM ) is ยฃ2.37 Billion. In 2024 the company made a revenue of ยฃ1.79 Billion an increase over the revenue in the year 2023 that were of ยฃ1.43 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Alnylam Pharmaceuticals from 2004 to 2024

Annual revenue

Year Revenue Change
2024ยฃ1.79 B24.84%
2023ยฃ1.43 B67.35%
2022ยฃ0.85 B37.1%
2021ยฃ0.62 B72.98%
2020ยฃ0.36 B115.76%
2019ยฃ0.16 B183.98%
2018ยฃ59.01 M-11.3%
2017ยฃ66.52 M74.07%
2016ยฃ38.21 M37.82%
2015ยฃ27.73 M-14.61%
2014ยฃ32.47 M13.57%
2013ยฃ28.59 M-30.73%
2012ยฃ41.28 M-22.47%
2011ยฃ53.24 M-17.84%
2010ยฃ64.8 M4.31%
2009ยฃ62.12 M-5.31%
2008ยฃ65.61 M156.1%
2007ยฃ25.62 M86.35%
2006ยฃ13.74 M314.78%
2005ยฃ3.31 M48.75%
2004ยฃ2.22 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Novartis
NVS
ยฃ41.99 B 1,665.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ35.21 B 1,380.50%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
ยฃ10.62 B 346.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
ยฃ1.78 B-24.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
ยฃ0.47 B-80.00%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
ยฃ12.78 B 437.62%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
ยฃ0.61 B-74.16%๐Ÿ‡บ๐Ÿ‡ธ USA